deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT03422068

This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF) on no Background Anti-fibrotic Therapy.

Sponsor: Boehringer Ingelheim

Conditions Idiopathic Pulmonary Fibrosis
Interventions BI 1015550 Placebo
Updated 25 times since 2018 Last updated: Nov 14, 2025 Started: Mar 16, 2018 Primary completion: Jul 1, 2019 Completion: Jul 10, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Idiopathic Pulmonary Fibrosis, this trial is completed. The trial is conducted by Boehringer Ingelheim and has accumulated 25 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Jan 2021 · 14 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 9 months · monthly snapshot

Change History

25 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE1

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

▶ Show 20 earlier versions

  1. Nov 2019 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  2. Oct 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE1

  3. Sep 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  4. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE1

  5. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE1

  6. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE1

  7. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE1

  8. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE1

  9. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE1

  10. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE1

  11. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE1

  12. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

  13. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE1

  14. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  15. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE1

  16. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE1

  17. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE1

  18. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1

  19. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  20. Mar 2018 — Apr 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Boehringer Ingelheim
Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Hanover, Germany , Heidelberg, Germany , Helsinki, Finland , L'Hospitalet de Llobregat, Spain , London, United Kingdom , Nieuwegein, Netherlands , Odense, Denmark , Roma, Italy , Rotterdam, Netherlands , Southampton, United Kingdom and 1 more location